Drugs / GM2-KLH
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00003357 | Jan 1998 → Nov 2001 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT00005052 | Dec 1999 → ? | cutaneous melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GM2-KLH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00005052 ↗ |
| Action | Deplete | “may make the body build an immune response to and kill tumor cells” NCT00003357 ↗ |
| Modality | Vaccine | “Vaccines made from GM2-KLH” NCT00003357 ↗ |
| Route | Subcutaneous | “GM2-KLH vaccine plus QS21 is administered subcutaneously to sites on the upper arm and upper leg” NCT00003357 ↗ |